2023;6(1): 613-622. doi:10.31488/bjcr.183
Results of a Phase I Study of Liposomal Annamycin for Treatment of R/R AML Patients after Induction Therapy
- Gil L, Wierzbowska A, Wróbel T, Maranda EL...
2023;6(1): 613-622. doi:10.31488/bjcr.183
Therapies for r/r AML are very limited, with poor outcomes. Anthracycline-based ...
2023;6(1): 623-628. doi:10.31488/bjcr.184
Introduction: Analysis of the most common prevalent symptoms among...
2023;6(2): 629-634. doi:10.31488/bjcr.185
Palliative Outcome Scale (POS) is an important tool to assess needs and priority...
2023;6(2): 635-641. doi:10.31488/bjcr.186
This protocol describes the use of advanced technologies for the assessment...
2023;6(2): 642-643. doi:10.31488/bjcr.187
Background: Pelvic chemoradiotherapy (CRT) is an effective treatment for...
2024;7(1): 644-647. doi:10.31488/bjcr.188
Objective: one of the essential regulators of carcinogenesis is MicroRNA-21 (miR-21)...
Professor
Department of Pathology
University of Arizona College of Medicine
Member, Arizona Cancer Center
Member, BIO5 Institute
British Journal of Cancer Research is an open access, peer-reviewed international journal with broad scope covering all areas of cancer research, cancer prevention, diagnosis, treatment and patient care.
British Journal of Cancer Research aims to facilitate rapid dissemination of novel discoveries in cancer research. Currently the journal is published bimonthly and accepts papers from authors worldwide. Our mission is to become the first choice for international researchers,clinicians, scientists, scholars and students to present their finest results, and to disseminate the results in the widest possible way and with high impact.
You can submit manuscript to British Journal of Cancer Research as Email attachment and expose your work to a wide international audience. Please direct queries on the submission process to the journal’s editorial office.